Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 29,129 matching trials from the live ClinicalTrials.gov search.
Conditions
Pancreatic Neoplasms
Interventions
DTA-H19
Biological
Lead sponsor
Anchiano Therapeutics Israel Ltd.
Industry
Eligibility
18 Years to 79 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Rett Syndrome
Interventions
ANAVEX2-73, Placebo
Drug
Lead sponsor
Anavex Life Sciences Corp.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Birmingham, Alabama • Sacramento, California • Chicago, Illinois + 5 more
Conditions
Glioblastoma Multiforme
Interventions
MGMTP140K-encoding retroviral vector, O6-benzylguanine, temozolomide, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Other + 2 more
Lead sponsor
Stanton Gerson MD
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Renal Impairment, Disease Severity
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Conditions
HIV Infections
Interventions
VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
35
States / cities
Bakersfield, California • Palm Springs, California • West Hollywood, California + 30 more
Completed Phase 1 Interventional Accepts healthy volunteers

VA106483 Dose Response Study in Elderly Males

NCT00922740
Conditions
Nocturia
Interventions
VA106483, Placebo
Drug
Lead sponsor
Vantia Ltd
Industry
Eligibility
65 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Type 1 Diabetes Mellitus
Interventions
LY2605541, Insulin Glargine
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions
Tovaxin Autologous T Cell Vaccine
Biological
Lead sponsor
Opexa Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Bellaire, Texas • Houston, Texas
Conditions
Leukemia
Interventions
MEK-162, Nilotinib, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1Phase 2 Interventional Results available

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

NCT02858310
Conditions
Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
Interventions
E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Conditions
Advanced Solid Tumors
Interventions
CP-868,596, Docetaxel, AG-013736
Drug
Lead sponsor
Arog Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Healthy
Interventions
Digoxin, Neratinib
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Terminated Phase 1Phase 2 Interventional Results available

Spinal Cord Injury Neuroprotection With Glyburide

NCT02524379
Conditions
Acute Spinal Cord Injury
Interventions
Glyburide
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Type 1 Diabetes
Interventions
Terbutaline
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
12 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Stanford, California • New Haven, Connecticut • Jacksonville, Florida + 3 more
Conditions
Myelodysplastic Syndromes, MDS/MPN Crossover Syndromes
Interventions
5-azacytidine, Decitabine
Drug
Lead sponsor
Benjamin Tomlinson
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Advanced Solid Tumor
Interventions
YL242, YL242; Pembrolizumab, YL242; 5-FU; LV, YL242; Pembrolizumab; 5-FU
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
New Haven, Connecticut • Sarasota, Florida • Boston, Massachusetts + 4 more
Conditions
Intracerebral Haemorrhage, Intraventricular
Interventions
Pioglitazone 15mg
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Head and Neck Cancer
Interventions
Docetaxel, Stereotactic Radiation
Drug · Radiation
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Lymphoma
Interventions
SAR245409
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Fort Meyers, Florida • Augusta, Georgia + 9 more
Conditions
Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Diseases
Interventions
Aripiprazole, Ingestible Event Marker (IEM)
Drug · Device
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
12
States / cities
Cerritos, California • Garden Grove, California • Long Beach, California + 9 more
Completed Not applicable Interventional Results available

Evaluation of a Carbon Nanotube Enabled Solid-State Head CT

NCT04495634
Conditions
Head Trauma
Interventions
Stationary Head CT (s-HCT)
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Hypertension, Impaired Glucose Tolerance
Interventions
AR9281, Placebo
Drug
Lead sponsor
Arete Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
30
States / cities
Mobile, Alabama • Muscle Shoals, Alabama • Anaheim, California + 26 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults

NCT05694533
Conditions
Healthy
Interventions
INDV-2000, Midazolam
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Opioid Pain Medication
Interventions
Tranexamic acid, Aminocaproic acid, Recombinant Human Thrombin, Lidocaine Hydrochloride with Epinephrine, Bupivacaine Hydrochloride with Epinephrine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York